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Abstract
Background
High-density lipoprotein (HDL) functionality and low-density lipoprotein (LDL) atherogenic
traits can describe the role of both particles on cardiovascular diseases more accurately
than HDL- or LDL-cholesterol levels. However, it is unclear how these lipoprotein properties
are particularly affected by different cardiovascular risk factors.
Objective
To determine which lipoprotein properties are associated with greater cardiovascular risk
scores and each cardiovascular risk factor.
Methods
In two cross-sectional baseline samples of PREDIMED trial volunteers, we assessed the
associations of HDL functionality (N = 296) and LDL atherogenicity traits (N = 210) with: 1)
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the 10-year predicted coronary risk (according to the Framingham-REGICOR score), and 2)
classical cardiovascular risk factors.
Results
Greater cardiovascular risk scores were associated with low cholesterol efflux values; oxi-
dized, triglyceride-rich, small HDL particles; and small LDLs with low resistance against oxi-
dation (P-trend<0.05, all). After adjusting for the rest of risk factors; 1) type-2 diabetic
individuals presented smaller and more oxidized LDLs (P<0.026, all); 2) dyslipidemic partici-
pants had smaller HDLs with an impaired capacity to metabolize cholesterol (P<0.035, all);
3) high body mass index values were associated to lower HDL and LDL size and a lower
HDL capacity to esterify cholesterol (P<0.037, all); 4) men presented a greater HDL oxida-
tion and lower HDL vasodilatory capacity (P<0.046, all); and 5) greater ages were related to
small, oxidized, cytotoxic LDL particles (P<0.037, all).
Conclusions
Dysfunctional HDL and atherogenic LDL particles are present in high cardiovascular risk
patients. Dyslipidemia and male sex are predominantly linked to HDL dysfunctionality, whilst
diabetes and advanced age are associated with LDL atherogenicity.
Introduction
Low levels of high-density lipoprotein (HDL) cholesterol (HDL-C) and high concentrations of
low-density lipoprotein (LDL) cholesterol (LDL-C) are traditionally related to a greater risk of
suffering a cardiovascular event [1]. However, HDL functions could reflect the protective role
of the lipoprotein better than HDL-C levels [2], and LDL characteristics provide further infor-
mation on the residual atherogenic risk of these particles beyond mere LDL-C concentrations
[3,4].
Both lipoprotein traits have been shown to be associated with high cardiovascular risk states
in very diverse ways. On the one hand, regarding HDL functions: 1) cholesterol efflux capacity
(HDL capacity to pick up cholesterol from peripheral cells) has demonstrated to be inversely
related with the incidence of cardiovascular events (and shown to predict these outcomes
more accurately than HDL-C concentrations) [5]; 2) deficiencies in the biological function of
two enzymes related to the metabolism of cholesterol in HDLs, lecithin-cholesterol acyltrans-
ferase (LCAT, responsible for the esterification and internalization of free cholesterol after
cholesterol efflux) and cholesteryl ester transfer protein (CETP, responsible for the exchange
of cholesterol from HDLs to other lipoproteins), have shown to be linked to modest incre-
ments (LCAT) or decrements (CETP) in the incidence of cardiovascular events [6,7], although
the effect of modifying these activities in other studies has not been shown to be conclusive
[8]; 3) the activity of paraoxonase-1 (PON1, an essential antioxidant HDL enzyme) has been
inversely associated with cardiovascular diseases incidence in some works [9] but not in others
[10]; 4) HDLs are also thought to promote endothelial protection and are linked to a greater
release of nitric oxide from endothelial cells [11], being this property transiently impaired in
acute coronary events [12]; finally, 5) HDL oxidation and its global lipid composition,
although being related to several aspects of a dysfunctional lipoprotein profile (a decreased
capacity to perform HDL biological functions or a decreased HDL stability) [13–16], have not
HDL function, LDL atherogenicity and cardiovascular risk
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been associated with high cardiovascular risk (CVR) states as clearly as other HDL functional
traits. On the other hand, regarding LDL atherogenic characteristics: 1) circulating levels of
oxidized LDLs are directly related with incidence of coronary diseases and all-cause mortality
[4,17], whilst low LDL resistance against oxidative modifications of the particle has been linked
with subclinical atherosclerosis and is present in high CVR subjects [18,19]; 2) small LDL par-
ticles (a characteristic deeply interrelated with a pro-atherogenic LDL profile, which can be
indirectly measured by the ratio between LDL-C and apolipoprotein B–ApoB–levels in circu-
lation [20]), have been associated with a greater incidence of cardiovascular events [21]; and 3)
compositional changes of LDL particles such as increases in their remnant triglyceride content
tend to increase ApoB-100 instability on LDL surface (which may lead to an inefficient binding
to LDL receptors) and have shown to be increased in coronary artery disease patients [22,23].
The aim of this study was to determine the independent associations of HDL functionality and
LDL atherogenic characteristics with: 1) the 10-year predicted risk of suffering a coronary
event (the Framingham-REGICOR CVR score), and 2) the most prevalent CVRFs (diabetes,
dyslipidemia, excess body weight, hypertension, and smoking habit), age, and sex, in high
CVR individuals.
Materials and methods
Study population
This study was a cross-sectional analysis in two sub-samples of volunteers from the PRE-
DIMED Study [24,25] at the baseline visit: one sample for the evaluation of HDL-related vari-
ables (N = 296) [26] and another for the assessment of LDL atherogenic traits (N = 210) [27].
The sample for the study of HDL-related parameters included the one in which the LDL-
related characteristics were assessed. In these populations, we registered the values of: 1) gen-
eral clinical variables (age, sex, body weight, height, blood pressure, and biochemical profile);
2) drug use; 3) adherence to a Mediterranean Diet, by means of the Mediterranean diet Score;
4) levels of physical activity according to the Minnesota Leisure Time physical Activity ques-
tionnaire; and 5) smoking habit [24,28]. In individuals aged 35–74, we calculated 10-year pre-
dicted risk of developing a future coronary event as the CVR scores according to the
Framingham-REGICOR equation validated for the Spanish population (considering age and
sex, presence of diabetes and tobacco habit, total and HDL-C levels, and blood pressure) [29].
Type-II diabetes mellitus was defined as the presence of an abnormal glucose metabolism or
use of anti-diabetic drugs. Dyslipidemia was defined as the presence of total cholesterol levels
�200 mg/dL or use of statins and triglyceride levels�150mg/dL. Hypertension was defined as
the presence of systolic blood pressure levels�140 mmHg, diastolic blood pressure levels�90
mmHg, or use of anti-hypertensive drugs. Body mass index (BMI) was calculated as the ratio
between weight (kg) and height squared (m2) [24].
Volunteers provided written informed consent before entering the trial. The study protocol
conforms to the ethical guidelines of the 1975 Declaration of Helsinki, was approved by the
local Research and Ethics Committee, and was registered with the International Standard Ran-
domized Controlled Trial Number ISRCTN35739639. Its details have been previously pub-
lished [24, 25].
HDL functionality determinations
We first isolated HDL particles from plasma by density gradient ultracentrifugation (isolated
HDL fraction) [26,30] and polyethylene glycol-induced precipitation of apolipoprotein B
(ApoB)-containing lipoproteins (ApoB-depleted plasma samples) [26]. Plasma, serum, isolated
HDL, and ApoB-depleted plasma samples were stored at -80˚C until use. We analyzed the
HDL function, LDL atherogenicity and cardiovascular risk
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participants’ lipid profile (triglycerides, cholesterol, HDL-C, and apolipoprotein A-I–
ApoA-I–) in an ABX-Pentra 400 autoanalyzer (Horiba ABX) [26]. We determined cholesterol
efflux capacity (HDL ability to pick up the cholesterol excess from cells) in a model of human
THP-1 monocyte-derived macrophages treated with ApoB-depleted plasma samples [26]. We
computed the ability of HDL lipoproteins to esterify cholesterol as the percentage of esterified
cholesterol in isolated HDL particles/lecithin cholesterol acyltransferase quantity in plasma
[26]. We determined the function of cholesteryl ester transfer protein (CETP) in plasma
[26,30] and the arylesterase activity of paraoxonase-1 (PON1) in serum [26] by commercial
kits. We assessed HDL vasodilatory capacity as the HDL-induced increment in the production
of nitric oxide in a human umbilical vein endothelial cell model treated with ApoB-depleted
plasma samples [26]. We determined the oxidation of HDL particles as the equivalents of mal-
ondialdehyde per mg/dL of cholesterol in ApoB-depleted plasma samples [26]. We examined
the lipid composition of the isolated HDL fraction in an ABX-Pentra 400 autoanalyzer (Horiba
ABX) and, from these data, we calculated the triglyceride/esterified cholesterol ratio in HDL
particles (“triglycerides in HDL core”) [26,30]. Finally, we assessed HDL size distribution by
LipoPrint technology (Quantimetrix) in plasma [26,30]. With the percentages of large and
small HDL particles (HDL2 and HDL3, respectively), we calculated the HDL2/HDL3 ratio.
LDL atherogenic traits
We first isolated LDL lipoproteins from plasma samples by density gradient ultracentrifuga-
tion [27,31] and stored them at -80˚C until use. From the values of the participants’ lipid pro-
file, we calculated LDL-C levels according to the Friedewald formula (whenever triglycerides
were<300 mg/dL) [27,31]. We quantified ApoB in an ABX-Pentra 400 autoanalyzer (Horiba
ABX) in plasma [27,31]B. We measured LDL resistance against oxidation (LDL lag time) from
the kinetics of formation of conjugated dienes (oxidized lipid forms) in isolated LDL samples
in a pro-oxidant environment [27,31]. We assessed the oxidation of LDL lipoproteins as the
equivalents of malondialdehyde per mg/dL of cholesterol in isolated LDL samples [27]. From
the lipid profile values, we calculated an approximation to LDL average size (the LDL-C/ApoB
ratio) [27]. We determined the lipid composition of isolated LDL particles in an ABX-Pentra
400 autoanalyzer (Horiba ABX) and, from these data, we calculated the triglyceride/total cho-
lesterol ratio in isolated LDL samples. Finally, we assessed LDL ex vivo cytotoxicity in a THP-1
monocyte-derived macrophage model as previously described [27].
Sample size
Accepting a type I error of 0.05, a type II error of 0.2, and a 1% loss rate in a two-sided contrast,
sample sizes of 196 and 140 participants provide sufficient statistical power to determine that
Pearson’s correlation coefficients�0.2 and�0.237 (for HDL- and LDL-related variables,
respectively) were significantly different from zero. Sample sizes were increased by 50%, up to
294 and 210 subjects, to allow adjustments for different covariates.
Statistical analyses
We first assessed the distribution of continuous variables using normality plots and
histograms.
To study the association between lipoprotein traits and CVR, we first compared the means
of HDL- and LDL-related variables among the CVR score groups (low risk–CVR score <5–,
moderate risk–CVR score�5 and <10–, and high risk–CVR score�10–) using a one-way
ANOVA for normally-distributed variables and a Kruskal-Wallis test for non-normally dis-
tributed ones. To determine possible linear associations between the CVR score group and the
HDL function, LDL atherogenicity and cardiovascular risk
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means or medians of lipoprotein-related variables, we performed Pearson’s or Spearman’s
tests, respectively, to calculate P-trend values.
We assessed the differences in the values of lipoprotein characteristics due to classical
CVRFs (presence of diabetes, dyslipidemia, hypertension, and tobacco use–categorical vari-
ables–; and greater values of BMI–continuous variable–), sex, and age (continuous variable),
in three multivariate linear regression models. Model 1 was non-adjusted. To determine the
independent effect of each of these traits on lipoprotein characteristics, model 2 was adjusted
for the rest of the previous factors, study site, adherence to the Mediterranean diet, and levels
of physical activity. Finally, model 3 included HDL-C or LDL-C levels as an extra co-variate, in
order to exclude the effect of lipoprotein cholesterol from the previous associations.
We accepted any two-sided P-value<0.05 as significant. We executed the previously
described analyses in R Software, version 3.4.1 (R: A language and environment for statistical
computing. R Foundation for Statistical Computing. Vienna, Austria).
Results
Participants
In accordance to the high CVR profile of the volunteers in the HDL functionality and LDL
atherogenicity subsamples, subjects were 65.9 and 65.4 years old, 49.0 and 51.4% of the partici-
pants were male, 49.0 and 47.1% were diabetic, 33.4 and 33.3% were under glucose-lowering
treatment, 77.4 and 79.0% were dyslipidemic, 44.9 and 43.3% were statin users, 78.7 and 82.4%
were hypertensive, 65.9 and 70.0% were under antihypertensive treatment, 44.9 and 44.8%
were obese, and 12.5 and 13.8% were smokers, respectively (Table 1).
HDL functionality, LDL atherogenicity, and CVR categories
Regarding HDL-related traits, high CVR was associated with low HDL-C and ApoA-I levels,
low cholesterol efflux values, high HDL oxidation, high content of triglycerides in HDL core
(P<0.001 in the five previous cases), and low values of the HDL2/HDL3 ratio (smaller HDL
size) (P = 0.002) (Fig 1).
Table 1. Baseline characteristics of the HDL functionality and LDL atherogenicity subsamples from volunteers of the PREDIMED study.
HDL functionality
subsample
(n = 296)a
LDL atherogenicity subsample
(n = 210)a
Age (years) 65.9 (6.43) 65.4 (6.60)
Male sex (%) 49.0% 51.4%
Diabetic individuals (%) 49.0% 47.1%
Glucose-lowering therapy users (%) 33.4% 33.3%
Dyslipidemic individuals (%) 77.4% 79.0%
Statin users (%) 44.9% 43.3%
Hypertensive individuals (%) 78.7% 82.4%
Antihypertensive therapy users (%) 65.9% 70.0%
Obesity (%) 44.9% 44.8%
Smoking habit:
Never smokers (%) 58.1% 56.2%
Smokers (%) 12.5% 13.8%
Former smokers (%) 29.4% 30.0%
aHDL indicates high-density lipoprotein; LDL, low-density lipoprotein
https://doi.org/10.1371/journal.pone.0218533.t001
HDL function, LDL atherogenicity and cardiovascular risk
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Regarding LDL-related variables, high CVR was associated with high ApoB levels (P = 0.025)
(but not with significant differences in LDL-C levels, P>0.05), low LDL resistance against oxi-
dation (low LDL lag time values) (P = 0.019), and low estimated LDL size (P = 0.001), and with
a borderline significant trend towards high LDL oxidation (P = 0.085) (Fig 2). Error bars depict
standard deviations.
Fig 1. Values of HDL functionality variables in the three groups according to CVR scores. Low CVR (score<5, N = 77), moderate
CVR (score�5 and<10, N = 115), and high CVR (score�10, N = 52). CVR indicates cardiovascular risk; HDL, high-density
lipoprotein.
https://doi.org/10.1371/journal.pone.0218533.g001
HDL function, LDL atherogenicity and cardiovascular risk
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Individual effects of CVRFs on lipoprotein traits in high CVR subjects
As observed in Fig 3, presence of type-II diabetes was associated with low HDL-C (P<0.001)
and ApoA-I levels (P = 0.004) and low cholesterol efflux capacity values (P = 0.001). Regarding
LDL properties (see Fig 4), diabetes was related to low LDL-C (P<0.001) levels, greater LDL
oxidation (P<0.001) and lower LDL resistance against oxidation (P = 0.007), lower estimated
LDL size (P<0.001) and a greater LDL triglyceride content (P = 0.032).
Dyslipidemia was related to greater cholesterol and apolipoprotein levels (P<0.05, all) and
high cholesterol efflux capacity values (P<0.001) (Figs 3 and 4).
High BMI values were associated with low HDL-C levels (P = 0.006), low HDL capacity to
esterify cholesterol (P = 0.008), smaller HDL size (P<0.001), and a greater triglyceride content
in the HDL core (P = 0.014). High BMI values were also linked to a lower estimated LDL size
after adjusting for all CVRFs. (P = 0.004).
Fig 2. Values of LDL functionality variables in the three groups according to CVR scores. Low CVR (score<5, N = 48), moderate
CVR (score�5 and<10, N = 88), and high CVR (score�10, N = 38). CVR indicates cardiovascular risk; LDL, low-density
lipoprotein. Error bars depict standard deviations.
https://doi.org/10.1371/journal.pone.0218533.g002
HDL function, LDL atherogenicity and cardiovascular risk
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Hypertension was not particularly associated with an abnormal lipoprotein profile (data
not shown), although it was independently linked to a borderline significant trend towards
low cholesterol efflux capacity values when adjusted for all classical CVRFs (P = 0.090). Finally,
Fig 3. Forest plots of the associations of cardiovascular risk factors with HDL functional properties. HDL indicates high-density lipoprotein. �: P<0.05; ��: P<0.01;
���: P<0.001.
https://doi.org/10.1371/journal.pone.0218533.g003
HDL function, LDL atherogenicity and cardiovascular risk
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being smoker was also unrelated to differences in any lipoprotein characteristic (data not
shown).
The exact coefficients of the associations of cardiovascular risk factors with lipoprotein
properties for the three models performed are available in S1 Table.
Effects of sex and age on lipoprotein traits in high CVR patients
Male sex was associated with a highly dysfunctional HDL profile (Fig 2 and S2 Table): after
adjusting for all classical CVRFs, men had lower HDL-C and ApoA-I levels (P<0.001, both),
lower cholesterol efflux capacity values (P = 0.003), lower CETP activities (P = 0.033), greater
HDL oxidation (P = 0.018), and smaller HDL particles (P = 0.004). Regarding LDLs, after
adjusting for CVRFs, male sex was linked to lower estimated LDL size (P = 0.028), and to
greater LDL oxidation (P = 0.044), cholesterol content (P = 0.009), and cytotoxicity
(P = 0.040). Finally, regarding HDL functionality, greater ages were related to larger HDL par-
ticles (P<0.001). Despite greater age being linked to low LDL-C and ApoB levels (P<0.001), it
Fig 4. Forest plots of the associations of cardiovascular risk factors with LDL pro-atherogenic traits. LDL indicates low-density lipoprotein. �: P<0.05; ��: P<0.01;
���: P<0.001.
https://doi.org/10.1371/journal.pone.0218533.g004
HDL function, LDL atherogenicity and cardiovascular risk
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was also independently associated with a greater LDL oxidation (P = 0.009), a greater LDL tri-
glyceride content (P = 0.037), and greater LDL cytotoxic potential (P = 0.030) when adjusting
for all classical CVRFs.
Discussion
Our data show that dysfunctional HDL and atherogenic LDL particles are associated with
greater CVR scores and particularly impaired in certain high CVR subjects (diabetic, dyslipi-
demic, with excess weight, male, and older) in the first systematic, comprehensive association
analysis performed to date.
HDL functions are intimately related to CVR according to previous human studies. In our
dataset, we have observed an association between high CVR and low cholesterol efflux, high
HDL oxidation, high triglyceride content in HDL core, and smaller HDL size. Cholesterol
efflux capacity has already shown to be related to high subclinical atherosclerosis and inci-
dence of cardiovascular diseases [5,32]. Regarding HDL oxidation, it has been previously asso-
ciated with high CVR states [13] as well as with decreased cholesterol efflux capacity values
[14]. A high triglyceride content in the HDL core has been shown to contribute to HDL insta-
bility; It leads to an imbalance in the electrostatic relationships of the lipoprotein, promoting
the detachment of ApoA-I from the HDL surface [15]. This fact could be associated with an
impaired HDL function. Finally, our data also agree with previous reports of low levels of large
HDLs in high CVR states [33].
Regarding LDL atherogenicity properties, LDL particles with smaller estimated size and
more prone to become oxidized were associated with greater CVR scores. This concurs with
previous evidence: small and oxidized LDL particles have been related to a greater coronary
risk [3,4]. A lower LDL resistance against oxidation (present in coronary disease patients [19])
could facilitate LDL oxidation. Otherwise, ApoB levels, but not LDL-C concentrations,
appeared to be significantly increased in high CVR states. This fact agrees with the hypothesis
that alternative measurements of LDL quantity in circulation (such as ApoB levels or LDL par-
ticle number) could be more accurate and reflect better the CVR derived from these athero-
genic lipoproteins [34].
Diabetes was strongly associated with dysfunctional lipoprotein characteristics in our
cohort: it was associated with oxidized, small, triglyceride-rich LDL particles and with
impaired cholesterol efflux capacity (although this association was lost when adjusting for
HDL-C levels). Diabetes is strongly related to a suboptimal lipid profile [35] and a pro-oxidant,
pro-inflammatory status that could contribute to promoting HDL dysfunctionality [36] and
LDL atherogenicity [37]. The fact that there was 5% fewer dyslipidemic patients and 9.3%
more individuals treated with statins in the group of diabetic individuals could contribute to
explaining their lower cholesterol levels.
Once adjusted for the effect of HDL-C concentrations, being dyslipidemic was indepen-
dently associated with greater CETP activity, lower HDL capacity to esterify cholesterol, and
smaller HDL size, in agreement with previous work [38]. Dyslipidemia was also independently
linked to LDL particles richer in triglycerides. Some authors consider this fact may be linked
to a subtype of triglyceride-rich remnant lipoproteins, markedly pro-atherogenic [39].
Other classical CVRFs were shown to impair lipoprotein characteristics in our dataset. On
the one hand, increased BMI values were independently associated with lower HDL-C levels,
lower HDL ability to esterify cholesterol, and triglyceride-rich, small HDL particles, as well as
with low estimated LDL size. Some of these lipoprotein characteristics had already been associ-
ated with excess body weight [40]. In addition, hypertriglyceridemic states in overweight or
obesity could facilitate the accumulation of triglycerides in HDL particles [40], possibly leading
HDL function, LDL atherogenicity and cardiovascular risk
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to the formation of more dysfunctional lipoproteins [15]. On the other hand, although the
associations were non-significant, our results also suggest hypertension could be related to a
lower cholesterol efflux capacity and to greater LDL oxidation, potential mechanisms to be
addressed in future trials.
Men are known to be more strongly affected by cardiovascular diseases than women [41],
hence a potentially deleterious effect of male sex on lipoprotein traits could be expected. In our
data, being male was independently associated with low HDL-C levels and, once the confound-
ing effect of HDL-C concentrations was considered, it was also linked to greater HDL oxida-
tion and a reduced HDL capacity to promote the endothelial release of nitric oxide, pointing
to two potential novel contributors for the increased CVR in men that should be checked in
further studied. In addition, male sex was linked to high concentrations of oxidized, small,
cytotoxic LDL lipoproteins, but the significant of these associations was blunted when adjust-
ing for LDL-C levels. These data agree with previous works reporting increased levels of small
[42] and oxidized [43] LDL particles in men.
Aging has been traditionally associated with lower cholesterol levels, particularly in LDL, in
parallel with a time-dependent increase in CVR [41,44]. Our data suggest that despite this cho-
lesterol decrease, greater age is independently associated with a highly atherogenic LDL profile
(with oxidized, small, triglyceride-rich, cytotoxic LDL particles). The possible conversion of
LDL into pro-atherogenic particles could explain why CVR keeps increasing throughout life.
The main strength of the present study is that it has comprehensively assessed the associations
of HDL functionality and LDL atherogenicity characteristics with HDL-C and LDL-C levels,
and the main factors modulating CVR. Moreover, all the relationships described in our regres-
sion models have been adjusted for the effect of the rest of CVRFs and modulators. However,
there are also limitations. First, its design was cross-sectional, it did not allow us to infer cau-
sality and we could only establish associations between lipoprotein characteristics and CVRFs
and modulators that should be addressed in future prospective studies. Second, our study sub-
jects were older and at high CVR, therefore results cannot be extrapolated to the general popu-
lation. To partially correct this limitation, we considered these factors as covariates in the
linear regression analyses. Third, we could not perform the association analyses between CVR
scores and HDL- and LDL-related characteristics in individuals aged�75 since the Framing-
ham-REGICOR equation only allows the calculation of CVR scores in subjects 35 to 74 years
old. Fourth, due to availability and technical issues, we were unable to analyze the HDL ability
to esterify cholesterol and CETP and PON1 activities, HDL size, and HDL vasodilatory capac-
ity in 67, 37, and 60 volunteers. Finally, we could not detect powerful associations between
hypertension or smoking and lipoprotein properties since only a small proportion of our vol-
unteers was non-hypertensive (17.6–21.3%) or a smoker (12.5–13.8%).
Conclusions
High CVR scores were associated with low cholesterol efflux capacity values, high HDL oxida-
tion, triglyceride-rich HDL cores, small HDL size, small estimated LDL size, and low LDL
resistance against oxidation. Among high CVR subjects, being dyslipidemic and male were
preferentially associated with a dysfunctional HDL profile, while being diabetic and older was
specially related to pro-atherogenic LDL particles. To date, this is the first study to comprehen-
sively analyze the independent associations between CVR and HDL- and LDL-related vari-
ables in humans. Our data reflect the pertinence of assessing HDL function and LDL
atherogenicity in clinical studies, since much more information can be provided by lipopro-
teins beyond HDL-C and LDL-C levels.
HDL function, LDL atherogenicity and cardiovascular risk
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